Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03234140




Registration number
NCT03234140
Ethics application status
Date submitted
26/07/2017
Date registered
31/07/2017
Date last updated
31/07/2017

Titles & IDs
Public title
Constitutional Genetics in Follicular Lymphoma
Scientific title
Constitutional Genetics to Predict Prognostic and Somatic Alterations in Follicular Lymphoma
Secondary ID [1] 0 0
69HCL17_0212
Universal Trial Number (UTN)
Trial acronym
CONPIL
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Follicular Lymphoma 0 0
Social Interaction 0 0
Genetic Predisposition to Disease 0 0
Condition category
Condition code

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Group "Genome Wide Association Studies" - Patients are adults, male or female, with a follicular lymphoma, homogeneously treated by immunochemotherapy included in one of the following cohorte :

* PRIMA Cohort : phase III (Sponsor LYSARC, France; NCT00140582): N=396
* RELEVANCE Cohort : phase III (Sponsor LYSARC, France; NCT01476787 ): N=441
* FOLL05 Cohort: phase III (Sponsor Italian lymphoma Foundation, Italy; NCT00774826): N=229
* MER1 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987): N=178
* MER2 Cohorts : prospective, observational (Sponsor Mayo Clinic, USA; IRB#09-001987):N=321

Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data.
Comparator / control treatment
Control group

Outcomes

Eligibility
Key inclusion criteria
Group "Genome Wide Association Studies"



* Follicular lymphoma treated in first line therapy treated by immunochemotherapy (PRIMA, FOL05, MER1 and 2, control arm of RELEVANCE trial)
* Follicular lymphoma treated in first line therapy by Rituximab and Lenalidomide as part of the investigational arm of RELEVANCE trial
* Available constitutional DNA samples for GWAS analysis with an accurate consent form for such genetic study
* Available biological and clinical characteristics at diagnosis with a follow-up of the patient for event free survival analysis
* 18 years of age or older
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* A non-follicular lymphoma histology according to WHO 2016 classification (grade 1, 2, 3a follicular lymphoma)
* Relapsed follicular lymphoma
* Patients without an accurate consent form for constitutional genetic study
* Patients with no available biological or clinical data and follow-up for the outcome analysis

Group "EPIC"

Inclusion Criteria:

* Included in the EPIC Cohort (European Prospective Investigation into Cancer and nutrition study between 1992 and 2000)
* Available constitutional DNA samples with an accurate consent form for such genetic study
* 18 years of age or older



* Patients without an accurate consent form for constitutional genetic study
* Patients with no available biological or clinical data and follow-up for the outcome analysis

Study design
Purpose
Duration
Selection
Timing
Retrospective
Statistical methods / analysis

Recruitment
Recruitment status
UNKNOWN
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
1/11/2017
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/11/2019
Actual
Sample size
Target
1883
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Primary sponsor type
Other
Name
Hospices Civils de Lyon
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Hervé Ghesquières, Pr
Address 0 0
Country 0 0
Phone 0 0
04 78 86 43 01
Fax 0 0
Email 0 0
herve.ghesquieres@chu-lyon.fr
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT03234140